July 9 (Reuters) - Moderna MRNA.O said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.

Here are the details:

• The agreement gives the participating countries - Austria, Denmark, Ireland, Luxembourg, Norway and Portugal - access to up to 24 million doses of the vaccine over as many as four years, the company said.

• The vaccine, mRESVIA, will be supplied in a ready-to-use, single-dose pre-filled syringe, making administration easier for healthcare professionals, Moderna said.

• The company had a similar joint procurement framework agreement with the European Commission for COVID-19 vaccines last year.

• mRESVIA is authorized in the European Union to prevent lower respiratory tract disease caused by RSV in adults.

• RSV is a common respiratory virus that causes seasonal infections such as the flu and is a leading cause of pneumonia and death in infants and older adults.

• Moderna has four approved mRNA vaccines for respiratory infections, including a combined influenza and COVID-19 vaccine authorized in Europe.